Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.

Autor:	Albain KS; Loyola University Chicago Stritch School of Medicine, Cardinal Bernadin Cancer Center, Loyola University Medical Center, Maywood, IL, USA., Gray RJ; Dana Farber Cancer Institute, Boston, MA, USA., Makower DF; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Faghih A; Thunder Bay Regional Health Science Centre, Thunder Bay, Ontario, Canada., Hayes DF; University of Michigan, Ann Arbor, MI, USA., Geyer CE; Houston Methodist Cancer Center, Houston, TX, USA., Dees EC; University of North Carolina, Chapel Hill, NC, USA., Goetz MP; Mayo Clinic, Rochester, MN, USA., Olson JA; University of Maryland School of Medicine, Baltimore, MD, USA., Lively T; National Institutes of Health, National Cancer Institute, Bethesda, MD, USA., Badve SS; Indiana University School of Medicine, Indianapolis, IN, USA., Saphner TJ; Aurora Health Care, Two Rivers, WI, USA., Wagner LI; Wake Forest University Health Service, Winston Salem, NC, USA., Whelan TJ; McMaster University, Hamilton, Canada., Ellis MJ; Baylor College of Medicine, Houston, TX, USA., Wood WC; Emory University, Atlanta, GA, USA., Keane MM; Cancer Trials Ireland, Dublin, Ireland., Gomez HL; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru., Reddy PS; Cancer Center of Kansas, Wichita, KS, USA., Goggins TF; Fox Valley Hematology and Oncology, Appleton, WI, USA., Mayer IA; Vanderbilt University, Nashville, TN, USA., Brufsky AM; University of Pittsburgh, Pittsburgh, PA, USA., Toppmeyer DL; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Kaklamani VG; University of Texas, San Antonio, TX, USA., Berenberg JL; University of Hawaii Cancer Center, Honolulu, HI, USA., Abrams J; National Institutes of Health, National Cancer Institute, Bethesda, MD, USA., Sledge GW; Stanford University, Stanford, CA, USA., Sparano JA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Jazyk:	angličtina
Zdroj:	Journal of the National Cancer Institute [J Natl Cancer Inst] 2021 Apr 06; Vol. 113 (4), pp. 390-399.
DOI:	10.1093/jnci/djaa148
Abstrakt:	Background: Black race is associated with worse outcomes in early breast cancer. We evaluated clinicopathologic characteristics, the 21-gene recurrence score (RS), treatment delivered, and clinical outcomes by race and ethnicity among women who participated in the Trial Assigning Individualized Options for Treatment. Methods: The association between clinical outcomes and race (White, Black, Asian, other or unknown) and ethnicity (Hispanic vs non-Hispanic) was examined using proportional hazards models. All P values are 2-sided. Results: Of 9719 eligible women with hormone receptor-positive, HER2-negative, node-negative breast cancer, there were 8189 (84.3%) Whites, 693 (7.1%) Blacks, 405 (4.2%) Asians, and 432 (4.4%) with other or unknown race. Regarding ethnicity, 889 (9.1%) were Hispanic. There were no substantial differences in RS or ESR1, PGR, or HER2 RNA expression by race or ethnicity. After adjustment for other covariates, compared with White race, Black race was associated with higher distant recurrence rates (hazard ratio [HR] = 1.60, 95% confidence intervals [CI] = 1.07 to 2.41) and worse overall survival in the RS 11-25 cohort (HR = 1.51, 95% CI = 1.06 to 2.15) and entire population (HR = 1.41, 95% CI = 1.05 to 1.90). Hispanic ethnicity and Asian race were associated with better outcomes. There was no evidence of chemotherapy benefit for any racial or ethnic group in those with a RS of 11-25. Conclusions: Black women had worse clinical outcomes despite similar 21-gene assay RS results and comparable systemic therapy in the Trial Assigning Individualized Options for Treatment. Similar to Whites, Black women did not benefit from adjuvant chemotherapy if the 21-gene RS was 11-25. Further research is required to elucidate the basis for this racial disparity in prognosis. (© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu